PE20211385A1 - Inhibidores de magl - Google Patents
Inhibidores de maglInfo
- Publication number
- PE20211385A1 PE20211385A1 PE2020001853A PE2020001853A PE20211385A1 PE 20211385 A1 PE20211385 A1 PE 20211385A1 PE 2020001853 A PE2020001853 A PE 2020001853A PE 2020001853 A PE2020001853 A PE 2020001853A PE 20211385 A1 PE20211385 A1 PE 20211385A1
- Authority
- PE
- Peru
- Prior art keywords
- alkyl
- hexafluoropropan
- piperazin
- oxy
- carbonyl
- Prior art date
Links
- 102100029814 Monoglyceride lipase Human genes 0.000 title abstract 2
- 101710116393 Monoglyceride lipase Proteins 0.000 title abstract 2
- 239000003112 inhibitor Substances 0.000 title 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 4
- -1 5-chloro-2 - ((4 - (((1,1,1,3,3,3- hexafluoropropan -2-yl) oxy) carbonyl) piperazin-1-yl) methyl) phenoxy Chemical group 0.000 abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 3
- 239000002253 acid Substances 0.000 abstract 1
- 229910052736 halogen Inorganic materials 0.000 abstract 1
- 125000005843 halogen group Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
- C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
- C07D295/182—Radicals derived from carboxylic acids
- C07D295/185—Radicals derived from carboxylic acids from aliphatic carboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/55—Acids; Esters
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D241/12—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D305/00—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms
- C07D305/02—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms not condensed with other rings
- C07D305/04—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D305/06—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D305/00—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms
- C07D305/02—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms not condensed with other rings
- C07D305/04—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D305/08—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Epidemiology (AREA)
- Rheumatology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Epoxy Compounds (AREA)
- Pyridine Compounds (AREA)
Abstract
Esta referido a compuestos de Formula I, en donde: R1 y R3 son H, alquilo C1-C6; R2 es alquilo C1-C6; R4 y R5 son H, alquilo C1-C6; R6 es halogeno, alquilo C1-C6, CN, OR7, entre otras opciones; p es 0, 1; n es 0, 1, 2, 3, 4. Entre los compuestos preferidos tenemos los siguientes: Acido 2-(5-cloro-2-((4-(((1,1,1,3,3,3- hexafluoropropan-2-il)oxi)carbonil)piperazin-1- il)metil)fenoxi)-2-metilpropanoico; Acido 3-(3-((4-(((1,1,1,3,3,3-hexafluoropropan-2-il)oxi)carbonil)piperazin-1-il)metil)-5-(trifluorometil)fenoxi)-2,2-dimetilpropanoico; Acido 2-(2-((4-(((1,1,1,3,3,3-hexafluoropropan- 2-il)oxi)carbonil)piperazin-1-il)metil)-5-(oxazol-2- il)fenoxi)-2-metilpropanoico; entre otros. Estos compuestos son moduladores de MAGL y se emplean en el tratamiento del dolor.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862671985P | 2018-05-15 | 2018-05-15 | |
PCT/US2019/032289 WO2019222266A1 (en) | 2018-05-15 | 2019-05-14 | Magl inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
PE20211385A1 true PE20211385A1 (es) | 2021-07-27 |
Family
ID=68534223
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PE2020001853A PE20211385A1 (es) | 2018-05-15 | 2019-05-14 | Inhibidores de magl |
Country Status (25)
Country | Link |
---|---|
US (3) | US11332453B2 (es) |
EP (1) | EP3793547A4 (es) |
JP (1) | JP2021523200A (es) |
KR (1) | KR20210010475A (es) |
CN (1) | CN112088001A (es) |
AR (1) | AR115092A1 (es) |
AU (1) | AU2019271123A1 (es) |
BR (1) | BR112020000863A2 (es) |
CA (1) | CA3097063A1 (es) |
CL (1) | CL2020002927A1 (es) |
CO (1) | CO2020013550A2 (es) |
CR (1) | CR20200545A (es) |
DO (1) | DOP2020000207A (es) |
EA (1) | EA202092586A1 (es) |
GE (1) | GEP20227443B (es) |
JO (1) | JOP20200276A1 (es) |
MA (1) | MA52635A (es) |
MX (1) | MX2020012158A (es) |
NI (1) | NI202000080A (es) |
PE (1) | PE20211385A1 (es) |
PH (1) | PH12020551934A1 (es) |
SG (1) | SG11202011228TA (es) |
TW (1) | TW201946906A (es) |
WO (1) | WO2019222266A1 (es) |
ZA (1) | ZA202006327B (es) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
HUE049690T2 (hu) | 2012-01-06 | 2020-10-28 | Lundbeck La Jolla Research Center Inc | Karbamátvegyületek és eljárások azok elõállítására és alkalmazására |
JP7042804B2 (ja) | 2016-09-19 | 2022-03-28 | ルンドベック ラ ホーヤ リサーチ センター,インク. | ピペラジンカルバメート、及びその製造と使用の方法 |
PL3793565T3 (pl) | 2018-05-14 | 2022-05-02 | Gilead Sciences, Inc. | Inhibitory MCL-1 |
CN112088001A (zh) | 2018-05-15 | 2020-12-15 | 隆德贝克拉荷亚研究中心有限公司 | Magl抑制剂 |
CN112638430B (zh) | 2018-06-27 | 2023-05-16 | 豪夫迈·罗氏有限公司 | 放射性标记的大麻素受体2配体 |
MA54827A (fr) * | 2019-01-25 | 2022-05-04 | H Lundbeck As | Méthodes de traitement d'une maladie à l'aide d'inhibiteurs de magl |
TWI778443B (zh) | 2019-11-12 | 2022-09-21 | 美商基利科學股份有限公司 | Mcl1抑制劑 |
US20210147367A1 (en) * | 2019-11-15 | 2021-05-20 | Lundbeck La Jolla Research Center, Inc. | Crystalline forms of a magl inhibitor |
CA3159951A1 (en) | 2019-11-26 | 2021-06-03 | Gilead Sciences, Inc. | Processes and intermediates for preparing mcl1 inhibitors |
EP4139288A1 (en) | 2020-04-21 | 2023-03-01 | H. Lundbeck A/S | Synthesis of a monoacylglycerol lipase inhibitor |
EP4198023A1 (en) | 2021-12-16 | 2023-06-21 | Basf Se | Pesticidally active thiosemicarbazone compounds |
WO2023156402A1 (en) | 2022-02-17 | 2023-08-24 | Basf Se | Pesticidally active thiosemicarbazone compounds |
Family Cites Families (43)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR1593586A (es) | 1967-10-17 | 1970-06-01 | ||
JPS6183073A (ja) | 1984-10-01 | 1986-04-26 | Oki Electric Ind Co Ltd | 印字装置の用紙送り方法 |
WO1989011794A1 (en) | 1988-06-07 | 1989-12-14 | Rikagaku Kenkyusho | Plant growth inhibitor |
WO1993011097A1 (en) | 1991-11-27 | 1993-06-10 | E.I. Du Pont De Nemours And Company | Herbicidal acylated amino-(phenyl- or pyridinyl- or thienyl-)-phenyl derivatives |
EP0736047B1 (en) | 1993-12-22 | 1998-03-04 | Shell Internationale Researchmaatschappij B.V. | Process for preparing carbamates |
JP2000500448A (ja) | 1995-11-15 | 2000-01-18 | ゼネカ リミテッド | 除草性置換ピラゾール化合物 |
WO1998000408A1 (en) | 1996-07-02 | 1998-01-08 | Novartis Ag | N-phenylimino heterocyclic derivatives and their use as herbicides |
RU2167150C2 (ru) | 1998-03-25 | 2001-05-20 | Фокин Александр Васильевич | Полифторалкил-n-арилкарбаматы, обладающие антимикробной активностью |
WO2001025188A1 (en) | 1999-10-04 | 2001-04-12 | University Of Medicine And Dentistry Of New Jersey | Novel carbamates and ureas |
EP1201298A1 (en) | 2000-10-24 | 2002-05-02 | Urea Casale S.A. | Carbamate condensation unit |
DE10348022A1 (de) | 2003-10-15 | 2005-05-25 | Imtm Gmbh | Neue Dipeptidylpeptidase IV-Inhibitoren zur funktionellen Beeinflussung unterschiedlicher Zellen und zur Behandlung immunologischer, entzündlicher, neuronaler und anderer Erkrankungen |
FR2864080B1 (fr) | 2003-12-23 | 2006-02-03 | Sanofi Synthelabo | Derives de 1-piperazine-et-1-homopiperazine-carboxylates, leur preparation et leur application en therapeutique |
WO2005063698A1 (en) | 2003-12-31 | 2005-07-14 | Council Of Scientific & Industrial Research | Process for preparing carbamates |
BRPI0507499A (pt) | 2004-02-18 | 2007-07-24 | Astrazeneca Ab | composto ou um sal farmaceuticamente aceitável ou hidrato dos mesmos, composição farmacêutica, uso do composto, e, métodos para tratar distúrbios mediados por mglur 5 e para inibir a ativação de receptores de mglur 5 |
CN101830899A (zh) | 2004-12-23 | 2010-09-15 | 霍夫曼-拉罗奇有限公司 | 杂环氨基甲酸酯衍生物,它们的制备及作为药剂的应用 |
ES2639621T3 (es) | 2004-12-30 | 2017-10-27 | Janssen Pharmaceutica N.V. | Derivados de fenilamida del ácido 4-(bencil)-piperazina-1-carboxílico y compuestos relacionados como moduladores de la amida hidrolasa de ácidos grasos (FAAH) para el tratamiento de la ansiedad, el dolor y otras afecciones |
EP1948630A2 (en) | 2005-11-05 | 2008-07-30 | AstraZeneca AB | Novel compounds |
JP2009523729A (ja) | 2006-01-13 | 2009-06-25 | ピーティーシー セラピューティクス,インコーポレーテッド | C型肝炎の治療方法 |
CN101679408B (zh) | 2006-12-22 | 2016-04-27 | Astex治疗学有限公司 | 作为fgfr抑制剂的双环杂环化合物 |
EP2124927A2 (en) | 2007-02-26 | 2009-12-02 | Kosan Biosciences Incorporated | Carbamate compounds |
US8188098B2 (en) | 2008-05-19 | 2012-05-29 | Hoffmann-La Roche Inc. | GPR119 receptor agonists |
AU2009270983A1 (en) | 2008-07-16 | 2010-01-21 | Schering Corporation | Bicyclic heterocycle derivatives and their use as GPCR modulators |
US8772318B2 (en) | 2008-11-14 | 2014-07-08 | The Scripps Research Institute | Methods and compositions related to targeting monoacylglycerol lipase |
CN102548558B (zh) | 2009-03-23 | 2014-04-30 | Msdk.K.公司 | 具有Aurora A选择性抑制作用的氨基吡啶衍生物 |
KR20110137831A (ko) | 2009-04-22 | 2011-12-23 | 얀센 파마슈티카 엔.브이. | 모노아실글리세롤 리파아제 억제제로서의 아제티디닐 다이아미드 |
UA107791C2 (en) | 2009-05-05 | 2015-02-25 | Dow Agrosciences Llc | Pesticidal compositions |
TWI506011B (zh) | 2009-11-03 | 2015-11-01 | Bayer Materialscience Ag | 在光聚合物調配物中作為添加劑之氟胺基甲酸酯 |
FR2960875B1 (fr) | 2010-06-04 | 2012-12-28 | Sanofi Aventis | Derives de carbamates d'hexafluoroisopropyle, leur preparation et leur application en therapeutique |
HUE049690T2 (hu) * | 2012-01-06 | 2020-10-28 | Lundbeck La Jolla Research Center Inc | Karbamátvegyületek és eljárások azok elõállítására és alkalmazására |
CN104114543B (zh) | 2012-01-06 | 2019-03-15 | 安吉奥斯医药品有限公司 | 治疗活性化合物及其使用方法 |
MX2014011134A (es) | 2012-03-19 | 2014-12-10 | Abide Therapeutics Inc | Compuestos de carbamato y preparacion y uso de los mismos. |
JP2014005245A (ja) | 2012-06-26 | 2014-01-16 | Dainippon Sumitomo Pharma Co Ltd | 二環性ピリミジン誘導体を含有する医薬組成物 |
US9551036B2 (en) | 2013-02-25 | 2017-01-24 | Whitehead Institute For Biomedical Research | Metabolic gene mesenchymal signatures and uses thereof |
WO2015003002A1 (en) | 2013-07-03 | 2015-01-08 | Abide Therapeutics, Inc. | Pyrrolo-pyrrole carbamate and related organic compounds, pharmaceutical compositions, and medical uses thereof |
WO2016014975A2 (en) | 2014-07-25 | 2016-01-28 | Northeastern University | Urea/carbamates faah magl or dual faah/magl inhibitors and uses thereof |
EP3271352B1 (en) | 2015-03-18 | 2021-05-12 | H. Lundbeck A/S | Piperazine carbamates and methods of making and using same |
JP7042804B2 (ja) | 2016-09-19 | 2022-03-28 | ルンドベック ラ ホーヤ リサーチ センター,インク. | ピペラジンカルバメート、及びその製造と使用の方法 |
JOP20190106A1 (ar) * | 2016-11-16 | 2019-05-09 | Lundbeck La Jolla Research Center Inc | مثبطات أحادي أسيل جليسرول ليباز (magl) |
EA201991086A1 (ru) * | 2016-11-16 | 2019-11-29 | Кристаллические формы ингибитора magl | |
JOP20190105A1 (ar) | 2016-11-16 | 2019-05-09 | Lundbeck La Jolla Research Center Inc | مثبطات أحادي أسيل جليسرول ليباز (magl) |
EA202090296A1 (ru) * | 2017-08-29 | 2020-08-03 | Лундбекк Ла-Хойя Рисерч Сентер, Инк. | Спироциклические соединения и способы их получения и применения |
CN112088001A (zh) | 2018-05-15 | 2020-12-15 | 隆德贝克拉荷亚研究中心有限公司 | Magl抑制剂 |
MA54827A (fr) | 2019-01-25 | 2022-05-04 | H Lundbeck As | Méthodes de traitement d'une maladie à l'aide d'inhibiteurs de magl |
-
2019
- 2019-05-14 CN CN201980031137.4A patent/CN112088001A/zh active Pending
- 2019-05-14 TW TW108116518A patent/TW201946906A/zh unknown
- 2019-05-14 KR KR1020207033709A patent/KR20210010475A/ko not_active Application Discontinuation
- 2019-05-14 AR ARP190101283A patent/AR115092A1/es unknown
- 2019-05-14 CA CA3097063A patent/CA3097063A1/en active Pending
- 2019-05-14 AU AU2019271123A patent/AU2019271123A1/en not_active Abandoned
- 2019-05-14 GE GEAP201915479A patent/GEP20227443B/en unknown
- 2019-05-14 CR CR20200545A patent/CR20200545A/es unknown
- 2019-05-14 WO PCT/US2019/032289 patent/WO2019222266A1/en active Application Filing
- 2019-05-14 SG SG11202011228TA patent/SG11202011228TA/en unknown
- 2019-05-14 US US17/055,079 patent/US11332453B2/en active Active
- 2019-05-14 EA EA202092586A patent/EA202092586A1/ru unknown
- 2019-05-14 MX MX2020012158A patent/MX2020012158A/es unknown
- 2019-05-14 JP JP2020564158A patent/JP2021523200A/ja not_active Ceased
- 2019-05-14 BR BR112020000863-0A patent/BR112020000863A2/pt not_active Application Discontinuation
- 2019-05-14 MA MA052635A patent/MA52635A/fr unknown
- 2019-05-14 PE PE2020001853A patent/PE20211385A1/es unknown
- 2019-05-14 US US16/412,212 patent/US10570106B2/en not_active Expired - Fee Related
- 2019-05-14 JO JOP/2020/0276A patent/JOP20200276A1/ar unknown
- 2019-05-14 EP EP19803143.7A patent/EP3793547A4/en not_active Withdrawn
-
2020
- 2020-01-10 US US16/739,642 patent/US11214557B2/en active Active
- 2020-10-12 ZA ZA2020/06327A patent/ZA202006327B/en unknown
- 2020-10-28 CO CONC2020/0013550A patent/CO2020013550A2/es unknown
- 2020-11-10 DO DO2020000207A patent/DOP2020000207A/es unknown
- 2020-11-11 CL CL2020002927A patent/CL2020002927A1/es unknown
- 2020-11-13 NI NI202000080A patent/NI202000080A/es unknown
- 2020-11-13 PH PH12020551934A patent/PH12020551934A1/en unknown
Also Published As
Publication number | Publication date |
---|---|
GEP20227443B (en) | 2022-11-25 |
MA52635A (fr) | 2021-03-24 |
DOP2020000207A (es) | 2021-02-15 |
CR20200545A (es) | 2020-12-17 |
US20200148653A1 (en) | 2020-05-14 |
SG11202011228TA (en) | 2020-12-30 |
AR115092A1 (es) | 2020-11-25 |
ZA202006327B (en) | 2022-06-29 |
CA3097063A1 (en) | 2019-11-21 |
JP2021523200A (ja) | 2021-09-02 |
EP3793547A1 (en) | 2021-03-24 |
US20190352273A1 (en) | 2019-11-21 |
EP3793547A4 (en) | 2021-11-17 |
BR112020000863A2 (pt) | 2020-12-08 |
KR20210010475A (ko) | 2021-01-27 |
CO2020013550A2 (es) | 2020-11-10 |
AU2019271123A1 (en) | 2020-11-26 |
MX2020012158A (es) | 2021-01-29 |
US20210206735A1 (en) | 2021-07-08 |
CL2020002927A1 (es) | 2021-03-05 |
CN112088001A (zh) | 2020-12-15 |
EA202092586A1 (ru) | 2021-03-10 |
WO2019222266A1 (en) | 2019-11-21 |
TW201946906A (zh) | 2019-12-16 |
US10570106B2 (en) | 2020-02-25 |
US11332453B2 (en) | 2022-05-17 |
JOP20200276A1 (ar) | 2020-11-02 |
PH12020551934A1 (en) | 2021-06-21 |
NI202000080A (es) | 2021-02-15 |
US11214557B2 (en) | 2022-01-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PE20211385A1 (es) | Inhibidores de magl | |
PE20211375A1 (es) | Compuestos de 4-aminoisoindolina-1,3-diona sustituidos y su uso para el tratamiento de linfoma | |
PE20191146A1 (es) | Inhibidores de magl | |
PE20030856A1 (es) | Esteres hidroxamato del acido n-(4-fenilsustituido)-antranilico | |
PE20091901A1 (es) | Activadores de glucoquinasa | |
PE20191792A1 (es) | Derivados de isoxazol como agonistas del receptor nuclear y usos de los mismos | |
PE20040987A1 (es) | Nuevos compuestos de oxazol y tiazol como inhibidores del factor de crecimiento transformador (tgf) | |
PE20061348A1 (es) | DERIVADOS DEL ACIDO PIRMIDINCARBOXILICO COMO MODULADORES DE PPAR-alfa | |
PE20071080A1 (es) | Compuestos de pirimidinona biciclicos como inhibidores de la integrasa de hiv | |
PE20050417A1 (es) | Compuestos que modulan la actividad de ppar y procedimientos de preparacion | |
PE20110588A1 (es) | Derivados de benzotiazol como agentes anticancerigenos | |
PE20090434A1 (es) | Derivados de sulfonil amida como inhibidores de quinasas | |
PE20121518A1 (es) | Bloqueantes de los canales de sodio dependientes de voltaje | |
PE20120780A1 (es) | Nicotinamida sustituida como moduladores kcnq2/3 | |
PE20020693A1 (es) | Agonistas del receptor alfa activado del proliferador de peroxisomas | |
PE20020585A1 (es) | Inhibidores de metaloproteinasa del tipo pirimidin-2,4,6-triona | |
PE20050598A1 (es) | Compuestos moduladores de cb1 | |
PE20070829A1 (es) | Inhibidores cetp heterociclicos | |
PE20090159A1 (es) | COMPUESTOS DERIVADOS DE ACIDO INDOL-PROPIONICO COMO MODULADORES PPARs | |
PE20020870A1 (es) | 6,7,8,9-tetrahidro-5h-benzocicloheptenil aminas aciladas | |
PE20060357A1 (es) | Compuestos y composiciones como moduladores de receptor activado de proliferador de peroxisoma (ppar) | |
PE20191108A1 (es) | Inhibidores selectivos de jak1 | |
PE20020504A1 (es) | N-acilsulfonamidas promotoras de apoptosis | |
PE20061049A1 (es) | Compuestos de n-sulfonilaminobencil-2-fenoxiacetamida como antagonistas del receptor de vanilloides tipo 1 (vr1) | |
PE20020386A1 (es) | Derivados de tetrazolil-fenil acetamida como activadores de glucoquinasa |